Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.48 |
| ▸ | PLA2G2C | Q5R387 | 4/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114161 | 0.86 | TDP1 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL536993 | 0.86 | TDP1 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL38659918 | 0.86 | TDP1 (0.45) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL24485595 | 0.85 | PLA2G2C (0.57) | CTSKPLA2G2CCTSS | |
| SCHEMBL2836699 | 0.85 | PLA2G2C (0.57) | CTSKPLA2G2CCTSS | |
| SCHEMBL19084258 | 0.84 | CA1 (0.53) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22405806 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22405809 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22405880 | 0.83 | CA1 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL31407501 | 0.82 | PPARA (0.52) | CTSKPLA2G2CCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | CTSK 1506/4885PLA2G2C 2384/4885CTSS 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.